Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis.
Baumann
Leslie S
LS
Halem
Monica L
ML
D000328:Adult; D001905:Botulinum Toxins / Q000009:adverse effects* / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D003680:Deglutition Disorders / Q000139:chemically induced* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006225:Hand; D006801:Humans; D006945:Hyperhidrosis / Q000175:diagnosis* / Q000188:drug therapy*; D007279:Injections, Subcutaneous; D008297:Male; D009465:Neuromuscular Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017060:Patient Satisfaction; D012075:Remission, Spontaneous; D018570:Risk Assessment; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014786:Vision Disorders / Q000139:chemically induced* / Q000503:physiopathology
D009465:Neuromuscular Agents; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A